These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25440394)

  • 1. The current place of aprotinin in the management of bleeding.
    Royston D
    Anaesthesia; 2015 Jan; 70 Suppl 1():46-9, e17. PubMed ID: 25440394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
    Henry D; Carless P; Fergusson D; Laupacis A
    CMAJ; 2009 Jan; 180(2):183-93. PubMed ID: 19050037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
    Fergusson DA; Hébert PC; Mazer CD; Fremes S; MacAdams C; Murkin JM; Teoh K; Duke PC; Arellano R; Blajchman MA; Bussières JS; Côté D; Karski J; Martineau R; Robblee JA; Rodger M; Wells G; Clinch J; Pretorius R;
    N Engl J Med; 2008 May; 358(22):2319-31. PubMed ID: 18480196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemostatic management for cardiac surgical patients in the post-aprotinin era].
    Tanaka K
    Masui; 2009 Mar; 58(3):288-97. PubMed ID: 19306629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid.
    Menichetti A; Tritapepe L; Ruvolo G; Speziale G; Cogliati A; Di Giovanni C; Pacilli M; Criniti A
    J Cardiovasc Surg (Torino); 1996 Aug; 37(4):401-7. PubMed ID: 8698787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of inhibitors of fibrinolysis.
    Verstraete M
    Drugs; 1985 Mar; 29(3):236-61. PubMed ID: 2580684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review and application of serine protease inhibition in coronary artery bypass graft surgery.
    Engles L
    Am J Health Syst Pharm; 2005 Sep; 62(18 Suppl 4):S9-14. PubMed ID: 16227196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.
    Mangano DT; Miao Y; Vuylsteke A; Tudor IC; Juneja R; Filipescu D; Hoeft A; Fontes ML; Hillel Z; Ott E; Titov T; Dietzel C; Levin J; ;
    JAMA; 2007 Feb; 297(5):471-9. PubMed ID: 17284697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
    J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass.
    Waldow T; Krutzsch D; Wils M; Plötze K; Matschke K
    Clin Hemorheol Microcirc; 2009; 42(4):269-77. PubMed ID: 19628892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic methods to reduce perioperative bleeding.
    Levy JH
    Transfusion; 2008 Mar; 48(1 Suppl):31S-38S. PubMed ID: 18302580
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
    Jakobsen CJ; Søndergaard F; Hjortdal VE; Johnsen SP
    Eur J Cardiothorac Surg; 2009 Nov; 36(5):863-8. PubMed ID: 19782573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.
    Peters DC; Noble S
    Drugs; 1999 Feb; 57(2):233-60. PubMed ID: 10188764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery.
    Mengistu AM; Röhm KD; Boldt J; Mayer J; Suttner SW; Piper SN
    Anesth Analg; 2008 Aug; 107(2):391-7. PubMed ID: 18633013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
    Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ
    Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aprotinin in cardiac surgery: more risks than usefulness?].
    Bremerich DH; Strametz R; Kirchner R; Moritz A; Zwissler B
    Anaesthesist; 2006 Sep; 55(9):989-92, 994-6. PubMed ID: 16874472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprotinin versus lysine analogues: the debate continues.
    Royston D
    Ann Thorac Surg; 1998 Apr; 65(4 Suppl):S9-19; discussion S27-8. PubMed ID: 9563397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
    Body SC; Mazer CD
    Anesth Analg; 2006 Dec; 103(6):1354-9. PubMed ID: 17122202
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemostatic drugs.
    Mannucci PM
    N Engl J Med; 1998 Jul; 339(4):245-53. PubMed ID: 9673304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.